{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T03:35:37Z","timestamp":1778124937982,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.drudis.2022.103471","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:10:09Z","timestamp":1672877409000},"page":"103471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Natural products in pursuing novel therapies of nonalcoholic fatty liver disease and steatohepatitis"],"prefix":"10.1016","volume":"28","author":[{"given":"Haiyan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qihao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8880-4948","authenticated-orcid":false,"given":"Qingzhong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2022.103471_b0005","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"Jama-J. Am. Med. Assoc."},{"key":"10.1016\/j.drudis.2022.103471_b0010","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease \u2013 a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drudis.2022.103471_b0015","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies","volume":"7","author":"Stefan","year":"2019","journal-title":"Lancet Diabetes Endo."},{"key":"10.1016\/j.drudis.2022.103471_b0020","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2022.103471_b0025","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.plipres.2012.11.002","article-title":"Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis","volume":"52","author":"Musso","year":"2013","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.drudis.2022.103471_b0030","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1021\/acs.jmedchem.9b01701","article-title":"The race to bash NASH: emerging targets and drug development in a complex liver disease","volume":"63","author":"Romero","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2022.103471_b0035","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","article-title":"Natural products in drug discovery: advances and opportunities","volume":"20","author":"Atanasov","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2022.103471_b0040","doi-asserted-by":"crossref","first-page":"11876","DOI":"10.1021\/acs.jmedchem.2c01037","article-title":"Design, synthesis, and biological evaluations of pyridyl 4,5,6,7-tetrahydro-4,7-methanobenzo[d]isoxazoles as potent and selective inhibitors of 11beta-hydroxylase","volume":"65","author":"Yin","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2022.103471_b0045","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s42004-022-00759-4","article-title":"Manipulations of phenylnorbornyl palladium species for multicomponent construction of a bridged polycyclic privileged scaffold","volume":"5","author":"Yin","year":"2022","journal-title":"Commun. Chem."},{"key":"10.1016\/j.drudis.2022.103471_b0050","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.bbrc.2016.03.019","article-title":"Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress","volume":"472","author":"Qiang","year":"2016","journal-title":"Biochem. Bioph. Res. Co."},{"key":"10.1016\/j.drudis.2022.103471_b0055","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/bph.13855","article-title":"Natural alkaloid bouchardatine ameliorates metabolic disorders in high-fat diet-fed mice by stimulating the sirtuin 1\/liver kinase B-1\/AMPK axis","volume":"174","author":"Rao","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2022.103471_b0060","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1016\/j.bmc.2015.05.057","article-title":"Discovery of natural alkaloid bouchardatine as a novel inhibitor of adipogenesis\/lipogenesis in 3T3-L1 adipocytes","volume":"23","author":"Rao","year":"2015","journal-title":"Bioorgan. Med. Chem."},{"key":"10.1016\/j.drudis.2022.103471_b0065","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31749","article-title":"Cordycepin ameliorates nonalcoholic steatohepatitis by activation of the AMP-activated protein kinase signaling pathway","volume":"74","author":"Lan","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2022.103471_b0070","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.bmcl.2014.04.112","article-title":"trans-Caryophyllene is a natural agonistic ligand for peroxisome proliferator-activated receptor-alpha","volume":"24","author":"Wu","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.drudis.2022.103471_b0075","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/bph.13722","article-title":"beta-Caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and metabolic dysregulation in mice","volume":"175","author":"Varga","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2022.103471_b0080","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2147\/DMSO.S242282","article-title":"Dual SGLT1\/SGLT2 inhibitor phlorizin ameliorates non-alcoholic fatty liver disease and hepatic glucose production in type 2 diabetic mice","volume":"13","author":"David-Silva","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.drudis.2022.103471_b0085","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1021\/jm900872z","article-title":"Structure-activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: potential impact in diabetes","volume":"53","author":"Genet","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2022.103471_b0090","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/bph.14570","article-title":"Betulinic acid alleviates endoplasmic reticulum stress-mediated nonalcoholic fatty liver disease through activation of farnesoid X receptors in mice","volume":"176","author":"Gu","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2022.103471_b0095","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.1021\/acs.jafc.0c01978","article-title":"20S-protopanaxatriol ameliorates hepatic fibrosis, potentially involving FXR-mediated inflammatory signaling cascades","volume":"68","author":"Song","year":"2020","journal-title":"J. Agr. Food Chem."},{"key":"10.1016\/j.drudis.2022.103471_b0100","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.phrs.2017.04.021","article-title":"Cycloastragenol improves hepatic steatosis by activating farnesoid X receptor signalling","volume":"121","author":"Gu","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.drudis.2022.103471_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173264","article-title":"Vitexin ameliorates chronic stress plub high fat diet-induced nonalcoholic fatty liver disease by inhibiting inflammation","volume":"882","author":"Li","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2022.103471_b0110","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.intimp.2018.01.029","article-title":"Activation of autophagy is required for Oroxylin A to alleviate carbon tetrachloride-induced liver fibrosis and hepatic stellate cell activation","volume":"56","author":"Chen","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.drudis.2022.103471_b0115","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1111\/jcmm.14528","article-title":"Kaempferol attenuates liver fibrosis by inhibiting activin receptor-like kinase 5","volume":"23","author":"Xu","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.drudis.2022.103471_b0120","article-title":"Ferulic acid ameliorates hepatic inflammation and fibrotic liver injury by inhibiting PTP1B activity and subsequent promoting AMPK phosphorylation","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drudis.2022.103471_b0125","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/aps.2010.64","article-title":"Leukamenin F suppresses liver fibrogenesis by inhibiting both hepatic stellate cell proliferation and extracellular matrix production","volume":"31","author":"Liu","year":"2010","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.drudis.2022.103471_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.622841","article-title":"Ginsenosides improve nonalcoholic fatty liver disease via integrated regulation of gut microbiota, inflammation and energy homeostasis","volume":"12","author":"Liang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drudis.2022.103471_b0135","doi-asserted-by":"crossref","first-page":"10878","DOI":"10.1021\/acsomega.0c00529","article-title":"Ginsenoside Rg1 regulates liver lipid factor metabolism in NAFLD model rats","volume":"5","author":"Hou","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.drudis.2022.103471_b0140","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/mnfr.201400399","article-title":"Ursolic acid improves lipid and glucose metabolism in high-fat-fed C57BL\/6J mice by activating peroxisome proliferator-activated receptor alpha and hepatic autophagy","volume":"59","author":"Jia","year":"2015","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.drudis.2022.103471_b0145","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1039\/C5FO00083A","article-title":"Ursolic acid inhibits the development of nonalcoholic fatty liver disease by attenuating endoplasmic reticulum stress","volume":"6","author":"Li","year":"2015","journal-title":"Food Funct."},{"key":"10.1016\/j.drudis.2022.103471_b0150","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.biopha.2017.10.153","article-title":"Protective effect of dioscin against thioacetamide-induced acute liver injury via FXR\/AMPK signaling pathway in vivo","volume":"97","author":"Zheng","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drudis.2022.103471_b0155","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.phrs.2018.03.017","article-title":"Dioscin alleviates non-alcoholic fatty liver disease through adjusting lipid metabolism via SIRT1\/AMPK signaling pathway","volume":"131","author":"Yao","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.drudis.2022.103471_b0160","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.phymed.2016.12.006","article-title":"Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor","volume":"25","author":"Duan","year":"2017","journal-title":"Phytomedicine"},{"key":"10.1016\/j.drudis.2022.103471_b0165","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1017\/S0007114510002266","article-title":"The inhibitory effect of genistein on hepatic steatosis is linked to visceral adipocyte metabolism in mice with diet-induced non-alcoholic fatty liver disease","volume":"104","author":"Kim","year":"2010","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.drudis.2022.103471_b0170","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.biopha.2019.01.004","article-title":"Genistein can ameliorate hepatic inflammatory reaction in nonalcoholic steatohepatitis rats","volume":"111","author":"Yin","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drudis.2022.103471_b0175","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000489166","article-title":"Grape leucoanthocyanidin protects liver tissue in albino rabbits with nonalcoholic hepatic steatosis","volume":"205","author":"Franklin","year":"2018","journal-title":"Cells Tissues Organs"},{"key":"10.1016\/j.drudis.2022.103471_b0180","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.201700303","article-title":"(-)-Epicatechin regulates blood lipids and attenuates hepatic steatosis in rats fed high-fat diet","volume":"61","author":"Cheng","year":"2017","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.drudis.2022.103471_b0185","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1096\/fj.201700602R","article-title":"Silybin inhibits NLRP3 inflammasome assembly through the NAD(+)\/SIRT2 pathway in mice with nonalcoholic fatty liver disease","volume":"32","author":"Zhang","year":"2018","journal-title":"FASEB J."},{"key":"10.1016\/j.drudis.2022.103471_b0190","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.biopha.2018.09.116","article-title":"Hepatoprotective effect of bisbenzylisoquinoline alkaloid tiliamosine from Tiliacora racemosa in high-fat diet\/diethylnitrosamine-induced non-alcoholic steatohepatitis","volume":"108","author":"Darvin","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drudis.2022.103471_b0195","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/08923973.2017.1327965","article-title":"Hepatoprotective effect of parthenolide in rat model of nonalcoholic fatty liver disease","volume":"39","author":"Bahabadi","year":"2017","journal-title":"Immunopharm. Immunot."},{"key":"10.1016\/j.drudis.2022.103471_b0200","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1124\/dmd.118.083691","article-title":"Berberine directly affects the gut microbiota to promote intestinal farnesoid X receptor activation","volume":"47","author":"Tian","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drudis.2022.103471_b0205","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1124\/mol.116.106617","article-title":"Orally administered berberine modulates hepatic lipid metabolism by altering microbial bile acid metabolism and the intestinal FXR signaling pathway","volume":"91","author":"Sun","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.drudis.2022.103471_b0210","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.lfs.2017.11.027","article-title":"Baicalin attenuates non-alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, inflammation and fibrosis in mice","volume":"192","author":"Zhang","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.drudis.2022.103471_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105444","article-title":"Baicalin and the liver-gut system: pharmacological bases explaining its therapeutic effects","volume":"165","author":"Hu","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.drudis.2022.103471_b0220","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.bbrc.2019.03.131","article-title":"Formononetin ameliorates cholestasis by regulating hepatic SIRT1 and PPAR alpha","volume":"512","author":"Yang","year":"2019","journal-title":"Biochem. Bioph. Res. Co."},{"key":"10.1016\/j.drudis.2022.103471_b0225","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1747-0285.2007.00606.x","article-title":"Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study","volume":"71","author":"Salam","year":"2008","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.drudis.2022.103471_b0230","article-title":"Aesculin protects against DSS-Induced colitis though activating PPAR gamma and inhibiting NF-kappa B pathway","volume":"857","author":"Tiana","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2022.103471_b0235","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.biopha.2017.07.086","article-title":"Potential of the chlorogenic acid as multitarget agent: insulin-secretagogue and PPAR alpha\/gamma dual agonist","volume":"94","author":"Sanchez","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drudis.2022.103471_b0240","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1021\/cb4003893","article-title":"Rutaecarpine analogues reduce lipid accumulation in adipocytes via inhibiting adipogenesis\/lipogenesis with AMPK activation and UPR suppression [published correction appears in ACS Chem. Biol. 2015;10:1570\u20131571]","volume":"8","author":"Chen","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.drudis.2022.103471_b0245","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/aps.2015.167","article-title":"Rutaecarpine ameliorates hyperlipidemia and hyperglycemia in fat-fed, streptozotocin-treated rats via regulating the IRS-1\/PI3K\/Akt and AMPK\/ACC2 signaling pathways","volume":"37","author":"Nie","year":"2016","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.drudis.2022.103471_b0250","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.phrs.2017.12.026","article-title":"Catalpol ameliorates hepatic insulin resistance in type 2 diabetes through acting on AMPK\/NOX4\/PI3K\/AKT pathway","volume":"130","author":"Yan","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.drudis.2022.103471_b0255","doi-asserted-by":"crossref","first-page":"628","DOI":"10.2337\/db12-0585","article-title":"Antidiabetic effects of Pterosin A, a small-molecular-weight natural product, on diabetic mouse models","volume":"62","author":"Hsu","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.drudis.2022.103471_b0260","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1002\/jcb.24232","article-title":"Promotion of adiponectin multimerization by emodin: a novel AMPK activator with PPAR gamma-agonist activity","volume":"113","author":"Chen","year":"2012","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.drudis.2022.103471_b0265","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1124\/mol.117.109900","article-title":"Identification of an oleanane-type triterpene hedragonic acid as a novel farnesoid X receptor ligand with liver protective effects and anti-inflammatory activity","volume":"93","author":"Lu","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.drudis.2022.103471_b0270","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1126\/science.1072891","article-title":"A natural product that lowers cholesterol as an antagonist ligand for FXR","volume":"296","author":"Urizar","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.drudis.2022.103471_b0275","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.bbrc.2005.08.159","article-title":"Xanthohumol, the chalcone from beer hops (Humulus lupulus L.), is the ligand for farnesoid X receptor and ameliorates lipid and glucose metabolism in KK-A(y) mice","volume":"336","author":"Nozawa","year":"2005","journal-title":"Biochem. Bioph. Res. Co."},{"key":"10.1016\/j.drudis.2022.103471_b0280","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.pharep.2019.01.008","article-title":"Antifibrotic effects of Fraxetin on carbon tetrachloride-induced liver fibrosis by targeting NF-kappa B\/IkB alpha, MAPKs and Bcl-2\/Bax pathways","volume":"71","author":"Wu","year":"2019","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.drudis.2022.103471_b0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tox.2018.01.007","article-title":"Natural product andrographolide alleviated APAP-induced liver fibrosis by activating Nrf2 antioxidant pathway","volume":"396","author":"Yan","year":"2018","journal-title":"Toxicology"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622004640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622004640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:02:57Z","timestamp":1761224577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644622004640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1359644622004640"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2022.103471","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural products in pursuing novel therapies of nonalcoholic fatty liver disease and steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2022.103471","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103471"}}